MedTrace Logo

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

NCT00777231 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-10-14

No results posted yet for this study

Summary

The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with Hemoglobinopathies to halt disease progression.

Conditions

Interventions

BIOLOGICAL

Enriched Hematopoetic Stem Cell Infusion

Enriched Hematopoetic Stem Cell Infusion

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • St. Christopher's Hospital for Children

    collaborator OTHER

  • The Western Pennsylvania Hospital

    collaborator OTHER

  • University of Florida

    collaborator OTHER

  • Medical College of Pennsylvania Hospital

    collaborator OTHER

  • Hahnemann University Hospital

    collaborator OTHER

  • Talaris Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Suzanne T Ildstad, M.D. · Talaris Therapeutics Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2010-08-31
Completion
2013-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00777231 on ClinicalTrials.gov